Tin tức & Cập nhật

Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.

Microvascular invasion and/or satellitosis (mVI/S) is independently associated with aggressive recurrence and mortality in hepatocellular carcinoma (HCC) patients treated with liver resection (LR), a recent study has shown.

Even modest alcohol consumption is associated with a higher risk of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at greater risk of developing incident hepatocellular carcinoma (HCC) when factors such as smoking, alcohol use, obesity, diabetes, and hypertension are present, according to a study. However, use of statin, metformin, or aspirin may modify disease progression.